March 27th 2024
Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Bell Discusses Options for a Patient With MSI-High, dMMR Endometrial Cancer
February 19th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Maria Bell, MD, MPH, MBA, moderated a discussion on biomarker testing and treatment for a patient with extensive, well-differentiated, grade 1 endometrioid adenocarcinoma.
Read More
Peer Discussion Addresses Challenges in Recurrent Endometrial Cancer Treatment
February 13th 2024During an in-person Community Case Forum event in New Jersey, Thomas Herzog, MD, and various participants discussed their approaches to molecular testing and treatment for patients with recurrent endometrial cancer.
Read More
Robotic Surgery Can Effectively Treat High-Risk EC After Prior Hysterectomy
January 30th 2024Robotic peritoneal mesometrial resection with targeted or systemic lymphadenectomy demonstrated feasibility with acceptable complication rates in intermediate/high-risk endometrial cancer requiring second surgery after prior hysterectomy.
Read More
Dostarlimab Plus SOC Chemo Meets Primary End Point in Advanced Endometrial Cancer
December 18th 2023Positive headline results from part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO trial support the potential use of dostarlimab as the backbone for therapies in mismatch repair proficient/microsatellite stable primary advanced or recurrent endometrial cancer.
Read More
Barroilhet Reviews New Endometrial Cancer Data of Later-Line Therapy
December 17th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Lisa Barroilhet, MD, MS, discussed recent trials that are relevant to a patient with recurrent endometrial cancer who relapsed less than a year after a complete response to doublet chemotherapy.
Read More
Anticipating Onset of Adverse Events Related to Lenvatinib/Pembrolizumab in Endometrial Cancer
December 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew A. Powell, MD, discussed management of adverse events with the combination of lenvatinib plus pembrolizumab in patients with endometrial cancer.
Read More
Factors Influencing Treatment Post-Chemo in dMMR Endometrial Cancer
November 9th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bradley Corr, MD, discussed the use of immune checkpoint inhibitors in patients with advanced endometrial cancer. This is the second of 2 articles based on this event.
Read More
Managing Adverse Events With Immune Checkpoint Inhibitors in Endometrial Cancer
November 5th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Paul A. DiSilvestro, MD, discussed with participants concerning the management of adverse events in a patient receiving single-agent immune checkpoint inhibitor for advanced mismatch-repair deficient endometrial cancer.
Read More
Dostarlimab Plus Chemo Betters OS in Endometrial Cancer
November 3rd 2023The combination of dostarlimab and chemotherapy demonstrated meaningful improvements in overall survival for the treatment of primary advanced or recurrent endometrial cancer, according to findings from the phase 3 RUBY trial.
Read More
Continued Benefit Shown With Pembrolizumab, Lenvatinib in Endometrial Cancer
October 23rd 2023An exploratory analysis of Study 309/KEYNOTE-775 showed further benefit for patients and consistent safety in patients who received pembrolizumab plus lenvatinib for advanced endometrial cancer who continued lenvatinib treatment.
Read More
Three of 4 Molecular Subgroups Respond to Dostarlimab in Advanced Endometrial Carcinoma
October 23rd 2023Findings from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial showed that patients with dMMR/MSI-H had a progression-free survival rate of 57.0% in the dostarlimab arm vs 10.2% in the placebo arm.
Read More
Evidence of Activity with Etigilimab Plus Nivolumab Seen in Recurrent/Advanced Solid Tumors
October 21st 2023The emergence of preliminary efficacy evidence, and potential biomarker targets, with the combination of the novel anti-TGIT agent etigilimab and nivolumab was presented at the 2023 ESMO Congress.
Read More
Durvalumab/Olaparib Maintenance Induces PFS Benefit in Advanced, Recurrent Endometrial Cancer
October 21st 2023Adding durvalumab to chemotherapy, followed by durvalumab and olaparib maintenance therapy improved progression-free survival in newly diagnosed advanced or recurrent endometrial cancer.
Read More
Atezolizumab Plus Chemo Improves PFS in Frontline, Advanced/Recurrent Endometrial Cancer
October 21st 2023The addition of atezolizumab to chemotherapy improved progression-free survival in frontline advanced or recurrent endometrial carcinoma, in particular, among patients with deficient mismatch repair status.
Read More
Considerations for Ordering Biomarker Testing in Endometrial Cancer
October 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bradley Corr, MD, discussed the importance of mismatch repair deficiency testing and the value of next-generation sequencing in patients with advanced endometrial cancer.
Read More
Arend Discusses Immune Checkpoint Inhibition for Recurrent dMMR Endometrial Cancer
October 17th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Rebecca Arend, MD, and participants discussed the use of single-agent immune checkpoint inhibitor as opposed to pembrolizumab plus lenvatinib in a patient with recurrent mismatch-repair deficient endometrial cancer.
Read More
Salani Reviews Options for a Patient With Metastatic Endometrial Cancer
September 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Ritu Salani, MD, MBA, discussed trials supporting the use of the immune checkpoint inhibitors pembrolizumab and dostarlimab in patients with metastatic endometrial cancer.
Read More
Physicians Discuss Immunotherapy Discontinuation in Endometrial Cancer
September 6th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed trials of immune checkpoint inhibition and when to discontinue treatment in patients with endometrial cancer. This is the second of 2 articles based on this event.
Read More